Alitair Pharmaceuticals Overview
- Founded
-
2010
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$6.16M
Alitair Pharmaceuticals General Information
Description
Developer of prescription cough medicines intended for bronchiectasis as well as leveraging their proprietary ion-exchange resin formulations. The company's patented formulation acts as a passive drug formulation system to reduce the risk of prescription drug overdose irrespective of the number of tablets or capsules ingested, enabling medical professionals to treat and patients to get relief from respiration-related diseases.
Contact Information
Website
www.alitairpharmaceuticals.com
Formerly Known As
The Cough Company
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Primary Office
- 99 Derby Street
- Suite 200
- Hingham, MA 02034
- United States
+1 (877) 000-0000
Alitair Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Later Stage VC (Series B) | 11-Nov-2020 | $6.16M | 00.000 | 000.00 | Completed | Clinical Trials - General |
Alitair Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 00.000 |
| Series A | 00,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 00.000 |
Alitair Pharmaceuticals Patents
Alitair Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20150265621-A1 | Treating bronchiectasis with doxofylline and erdosteine | Inactive | 22-Mar-2014 | 0000000000 | 0 |
| US-9211292-B2 | Preventing or reducing drug abuse and overdose events | Active | 05-Aug-2011 | 0000000000 | 0 |
| US-20130096191-A1 | Benzonatate compositions and methods of use | Active | 20-Oct-2010 | 0000000000 | |
| US-8808743-B2 | Benzonatate compositions and methods of use | Active | 20-Oct-2010 | 0000000000 | |
| US-20150150809-A1 | Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high ph environments | Inactive | 03-Sep-2010 | A61K9/209 |
Alitair Pharmaceuticals Executive Team (6)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| James Hoyes | Chief Executive Officer & Chairman | ||
| Helmut Albrecht MD | Chief Scientific Officer & Consultant |
Alitair Pharmaceuticals Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| James Hoyes | Alitair Pharmaceuticals | Chief Executive Officer & Chairman | 000 0000 |
| Robert Casale | Alitair Pharmaceuticals | Board Member | 000 0000 |
Alitair Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
